Newsroom

2019 · 2018 · 2017 · 2016 · 2015 · 2014 · 2013 ·
  • The new website of Geistlich Pharma AG has been live since today. With the re-launch, the information content has been tailored even more specifically to the information requirements of specialist clinic personnel and their patients. In addition to product information, therapy concepts with case studies and easy-to-understand video material are also available. Furthermore, the website has a fresher design and a more user-friendly web architecture.

  • Have you ever ‘sealed’ an extraction socket with a golf ball? Those who want to approach ridge preservation in a different way will have the opportunity to do so at the Geistlich booth during the ITI World Symposium in Geneva.

  • An idea is just the starting point. So how is it developed into a finished product? Experience the entire process from A to Z at Geistlich Pharma. In a new film, Chief Science Officer Terance Hart takes the audience behind the scenes of the company.

  • In 2013, the global economy was once again characterised by uncertainty and reticence. In this difficult environment, Geistlich Pharma AG again asserted itself very well as a Swiss SME. The company posted solid growth and strengthened or even expanded its position in virtually all its markets. Once again, the balanced geographical mix, an attractive product pipeline and the operational strength of the company were contributing factors.

  • Achieve optimal bone and soft tissue regeneration following tooth extraction without punching soft tissue from the palate – with the combination of Geistlich Bio-Oss® Collagen and Geistlich Mucograft® Seal. Swiss expert PD Dr. Ronald E. Jung demonstrates his technique in a surgical video.

  • Innovation is an everyday occurrence at Geistlich. The film “The Art of Innovation” is designed to give a better idea of what this everyday life looks like and to make it accessible to the public at large.

  • Following on from the bone replacement material Geistlich Bio-Oss®, the Japanese authorities have now also granted a licence to Geistlich Bio-Gide®. The sales launch of the collagen membrane for bone regeneration is to take place shortly.

  • With immediate effect two new laws in the US and France will regulate collaboration between medicine and industry. The goal of both laws is to ensure greater transparency in future towards the general public and thus prevent conflicts of interest. All payments from manufacturers to the medical profession will be published on the Internet.

  • In October 2013, Dr Peter Geistlich, the President of the Board of Directors of Geistlich Pharma AG, together with Geistlich Pharma AG in the USA, launched the Osteo Science Foundation which has its registered office in Philadelphia. The goal of the Foundation is to support and promote independent research in North America in oral and maxillofacial surgery and to put its results from theory into practice.

  • In September, the 3rd Central Switzerland Economic Forum was held on the Pilatus on the topic of "Education – Innovation – Workforce". Paul Note, CEO of Geistlich Pharma AG, was the podium guest at the workshop "Innovation and knowledge transfer". With renowned representatives from business and education, he discussed the topic: What promotes innovations and drives the transfer of knowledge; where are the obstacles?

PRESS CONTACT
Dr. Mirjam Kessler
Director Corporate Communications